Vasopressin and desmopressin in central diabetes insipidus: Adverse effects and clinical considerations

Pediatric Endocrinology Reviews

Volumn 2, Issue SUPPL. 1, 2004, Pages 115-123

  Kim, Roy J ^a   Malattia, Clara ^b   Allen, Michaela ^b   Moshang Jr , Thomas ^a,c   Maghnie, Mohamad ^b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Adverse effects; Children; Desmopressin; Diabetes insipidus; Vasopressin

Indexed keywords

ARGIPRESSIN; DESMOPRESSIN; VASOPRESSIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AGITATION; BEHAVIOR DISORDER; BRONCHOSPASM; BURNING SENSATION; DELUSION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EPISTAXIS; ERYTHEMA; FATIGUE; GANGRENE; HEART ARREST; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HORMONAL THERAPY; HUMAN; HYPERHIDROSIS; HYPERNATREMIA; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INJECTION SITE REACTION; INTESTINAL DYSMOTILITY; INTESTINE MOTILITY; NAUSEA; NEUROGENIC DIABETES INSIPIDUS; NOSE CONGESTION; PATIENT MONITORING; PREMATURE LABOR; REVIEW; RHINITIS; SEIZURE; SERUM OSMOLALITY; TACHYCARDIA; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOSIS; TREMOR; URTICARIA; VASCULAR HEADACHE; VERTIGO; VOMITING; WATER INTOXICATION;

ANTIDIURETIC AGENTS; CHILD; DEAMINO ARGININE VASOPRESSIN; DIABETES INSIPIDUS, NEUROGENIC; HUMANS; VASOPRESSINS;

EID: 12344258648     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Vasopressin injection, USP package insert, American Regent Laboratories, Inc., August 1998
2. Holmes CL, Patel BM, Russell JA and Walley KR. Physiology of vasopressin relevant to management of septic shock [see comment]. Chest 2001;120:989-1002
3. Jard S. Vasopressin receptors. A historical survey. Adv Exp Med Biol 1998;449:1-13
4. Baylis P, Cheetham T. Diabetes insipidus. Arch Dis Child 1998;79:84-9
5. Vasopressin. In: eds. AHFS Drug Information. Bethesda, MD: American Society of Health System Pharmacists Inc., 2002;3082-5
6. Lee W, Lippe B, La Franchi S, Kaplan S. Vasopressin analog DDAVP in the treatment of diabetes insipidus. American Journal of Disease in Childhood 1976;130:166-9
7. Kauli L, Laron I. A vasopressin analogue in treatment of diabetes insipidus. Arch Dis Child 1974;49:482-5
8. Lune S and Mamet Y. Transient myocardial ischemia may occur following subendometrial vasopressin infiltration. Eur J Obstet Gynecol Reprod Biol 2000;91:87-9
9. Anderson J, Johnston G. Development of cutaneous gangrene during continuous peripheral infusion of vasopressin. British medical Journal Clinical Research Ed 1983;287:1657-8
10. Akerlund M. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea. Prog Brain Res 2002;139:359-65
11. Bossmar T. Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban. J Perinat Med 1998;26:458-65
12. Vavra I, Machova A, Holecek V, Cort JH, Zaoral M, Sorm F. Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus. Lancet 1968;1:948-52
13. Horris A. Clinical experience with desmopressin: efficacy and safety in central diabetes insipidus and other conditions. J Pediatr 1989;114:711-8
14. Westsren U, Wittstrom C, Harris A. Oral desmopressin in central diabetes insipidus. Arch Dis Child 1986;61:247-50
15. Boulgourdjian E, Martinez A, Sopelato M, Heinrich J, Bergada C. Oral desmopressin treatment of central diabetes insipidus in children. Acta Paediatr 1997;86:1261-2
16. Fjellestad A, Czernichow P. Central diabetes insipidus in children. V. Oral treatment with a vasopressin hormone analogue (DDAVP). Acta Paediatr Scand 1986;75:605-10
17. Rizzo V, Albanese A, Stanhope R. Morbidity and mortality associated with vasopressin replacement therapy in children. J Pediatr Endocrinol Metab 2001;14:861-7
18. DDAVP Tablets Package Insert, Aventis Pharmaceuticals Inc., 2002
19. Robinson A, Verbalis J. In: Larsen, eds. Williams Textbook of Endocrinology 2003;281-300
20. Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf) 1993;38:177-82
21. Desmopressin Acetate (injection 4ug/mL) Package Insert, Ferring Pharmaceuticals Inc., 1998
22. Grossman A, Fabbri A, Goldberg P, Besser G. Two new modes of desmopressin (DDAVP) administration. BMJ 1980;280:1215
23. Kappy MS, Sonderer E. Sublingual administration of desmopressin: effectiveness in an infant with holoprosencephaly and central diabetes insipidus. American Journal of Diseases of Children 1987;141:84-5
24. Ball SG, Vaidja B, Baylis P. Hypothalamic adipsic syndrome: diagnosis and management. Clinical Endocrinology 1997;47:405-9
25. Andersson K, Arner B. Effects of DDAVP, a synthetic analogue of vasopressin, in patients with cranial diabetes insipidus. Acta Med Scand 1972;192:21-7
26. Edwards C, Kitau M, Chard, T, Besser G. Vasopressin analogue DDAVp in diabetes insipidus: clinical and laboratory studies. BMJ 1973;3:375-8
27. Aronson A andersson K, Bergstrand C, Mulder J. Treatment of diabetes insipidus in children with DDAVP, a synthetic analogue of vasopressin. Acta Paediatr Scand 1973;62:133-40
28. Becker D, Foley T. 1-Deamino08-D-arginine vasopressin in the treatment of central diabetes insipidus in childhood. J Pediatr 1978;92:1011-8
29. Mewasingh L, Aylett S, Kirkham F, Stanhope R. Hyponatraemia associated with lamotrigine in cranial diabetes insipidus. Lancet 2000;356:656
30. Maghnie M, Genovese E, Lundin S, Bonett F, Arico M. Iatrogenic extrapontine myelinolysis in central diabetes insipidus: are cyclosporin and 1-desamino-8-D-arginine vasopressin harmful in association? J Clin Endocrinol Metab 1997;82:1749-51
31. Salvatoni A, Maghnie M, Lorini R, Marni E. Hyponatremia and seizures during desmopressin acetate treatment in hypothyroidism. J Pediatr 1990;116:835-6
32. Cattaneo M. Review of clinical experience of desmopressin patients with congenital and acquired bleeding disorders. European Journal of Anaesthesiology, Suppl 1997;14:10-4,4-8
33. Lowe G. Desmopressin and myocardial infarction. Lancet 1989;1:895-6
34. Mannucci P, Lusher J. Desmopressin and thrombosis. Lancet 1989;2:675-6
35. Itabashi A, Katayama S, Yamaji T. Hypersensitivity to chlorobutanol in DDAVP solution. Lancet 1982;1:108
36. Von Gontard A, Lehmkuhl G. Desmopressin side effects. Child and Adolescent PsychiatrChild and Adolescent Psychiatric Clinics of North America 1996;35:129-30
37. Vie P, Queinnec C, Durelle-Caillared P, Broch C, Blondin G, Blayo M, Broussine L. Troubles du comportement chez un enfant traite par desmopressine puor enuresie. Arch Pediatr 2000;7:1128-9
38. Desmopressin Acetate. In: eds. AHFS Drug Information. Bethesda MD: American Society of Health System Pharmacists Inc, 2002;3078-82
39. Robinson A. DDAVP in the treatment of central diabetes insipidus. N Engl J Med 1974;294:507-11
40. Cobb W, Spare S, Reichlin S. Neurogenic diabetes insipidus: management with dDAVP. Ann Intern Med 1978;88:183-8
41. Ziai F, Walter R, Rosenthal I. Treatment of central diabetes insipidus in adults and children with desmopressin. Arch Intern Med 1978;138:1382-5
42. Williams T, Lightman SL, Leadbeater MJ. Hormonal and cardiovascular responses to DDAVP in man. Clin Endocrinol (Oxf) 1986;24:89-96
43. Vokes T, Gaskill M, Robertson G. Antibodies to vasopressin in patients with diabetes insipidus. Implications for diagnosis and therapy. Ann Intern Med 1988;108:190-5
44. Hime M, Richardson J. Diabetes insipidus and pregnancy: case report, incidence and review of literature. Obstet Gynecol Surv 1978;6:375-9
45. Lindheimer M, Davidson J. Osmoregulation, the secretion of arginine vasopressin and its metabolism during pregnancy. European Journal of Endocrinology 1995;132:133-43
46. Ray J, Boskovic R, Knie B, Hard M, Portnoi G, Koren G. In vitro analysis of human transplacental transport of desmopressin. Clin Biochem 2004;37:10-3
47. Robinson J, Sullivan F, Smith R, eds. Embryopathic activity of drugs. London:Churchill, 1965;110
48. Jost A. Sur le role de la vasopressine et de la corticostimuline (ACTH) dans la production of experimentale de lesions des extremites foetales (hemorragies, necroses, amputations conenitales). CR Soc Biol 1951;145:1805-9
49. Love A, Vickers T. Vasopressin induced dysmelia in rats and its relation to amniocentesis dysmelia. Br J Exp Pathol 1973;54:291-7
50. Chernoff N. Physiological and teratological effects of epinephrine and vasopressin on the fetal rat. Diss Abstr InT B 1970;30:3493 (quoted from Schardein JL, Chemically induced birth defects. New York: Marcel Dekker, 1985)
51. Chernoff N. Physiological and teratological effects of epinephrine and vasopressin on the fetal rat. Diss Abstr InT B 1970;30:3493 (quoted from Schardein JL, Chemically induced birth defects. New York: Marcel Dekker, 1985)
52. Carfagno S, Durant T, Shuman C. Diabetes insipidus in pregnancy. AMA Archives of Internal Medicine 1953;92:542-53
53. Campbell J. Diabetes insipidus and complicated pregnancy. JAMA 1980;243:1744-5
54. Sack J, Friedman E, Katznelson D, Frenkel T. Long-term treatment of diabetes insipidus with a synthetic analogue of vasopressin during pregnancy. Isr J Med Sci 1980;16:406-7
55. Cap R, Luscher K. Schwangerschaft bei diabetes insipidus-ein Fallbericht mit Literaturubersicht. Zentralbl Gynakol 1990;112
56. Linder N, Maloth I, Ohel G, Yourish O, Tamir I. L-deamino-8-d-arginine treatment in pregnancy and neonatal outcome. Am J Perinatol 1986;3:165-7
57. Källen BA, Carlsson SS, Bengtsson BK. Diabetes insipidus and use of desmopressin (Minirin) during pregnancy. European Journal of Endocrinology/European Federation of Endocrine Societies 1995;132:144-6
58. Ray J. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998;53:450-5
59. Burrow C, Wassenaar W, Robertson C, Sehl H. DDAVP treatment of diabetes insipidus during pregnancy and the post-partum period. Acta Endocrinol (Copenh) 1981;97:23-5
60. Ferry R, Kesavulu V, Kelly A, Levitt-Katz L, Moshang T. Hyponatremia and polyuria in children with central diabetes insipidus: challenges in diagnosis and management. J Pediatr 2001;138:744-7
61. Laredo S, Yuen K, Sonnenberg B, Halperin ML. Coexistence of central diabetes insipidus and salt wasting: the difficulties in diagnosis, changes in natremia and treatment. Journal of the American Society of Nephrology 1996;7:2527-32
62. Berger TM, Kistler W, Berendes E, Raufhake C, Walter M. Hyponatremia in a pediatric stroke patient: syndrome of inappropriate antidiuretic hormone secretion or cerebral salt wasting? Critical Care Medicine 2002;30:792-5
63. Donoghue MB, Latimer ME, Pillsbury HL, Hertzog JH. Hyponatremic seizure in a child using desmopressin for nocturnal enuresis. Arch Pediatr Adolesc Med 1998;152:290-2
64. Schulman SL, Stokes A, Salzman PM. The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis. J Urol 2001;166:2427-31
65. Wolfish NM, Barkin J, Gorodzinsky F, Schwarz R. The Canadian Enuresis Study and Evaluation-short- and long-term safety and efficacy of an oral desmopressin preparation. Scand J Urol Nephrol 2003;37:22-7
66. Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children, update of Cochrane Database Syst Rev 2000;(2):CD002112; PMID: 10796860]. Cochrane Database Syst Rev 2002:CD002112
67. Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children, update of Cochrane Database Syst Rev 2000;(2):CD002112; PMID: 10796860]. Cochrane Database Syst Rev 2002:CD002112